Q-omics provides the consensus-scored DYNLT3P1 profile across patient tissues and cancer cell-line models. DYNLT3P1 expression is associated with patient survival in 10 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, DYNLT3P1 is differentially expressed in 3, with the highest sampling consensus in THCA. Additionally, DYNLT3P1 RNA expression shows 7,256 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight BLCA, THCA, and GBM as cancer lineages where DYNLT3P1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DYNLT3P1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DYNLT3P1 survival associations across molecular data types. DYNLT3P1 RNA expression shows survival associations in the most cancer types (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DYNLT3P1 RNA expression–survival associations across cancer types. High DYNLT3P1 expression shows unfavorable associations in KIRC, LAML, LIHC and PAAD, but favorable associations in BLCA and LUSC. The BLCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify BLCA as the clearest survival context for DYNLT3P1 RNA expression.
This table summarizes DYNLT3P1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for DYNLT3P1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DYNLT3P1 shows lower tumor expression in KIRC and higher tumor expression in THCA and COAD. The THCA box plot shows higher DYNLT3P1 RNA expression in tumor versus normal tissue (log2 FC = +0.433, t-test p < 0.001).
This table shows molecular features associated with DYNLT3P1 in patient tissues and cancer cell lines. In patient samples, DYNLT3P1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set.
